ArcherDX Promises Precision Oncology For All

Trying to monitor what’s happening in the disruptive technology space is a difficult task, especially in the broad area of life sciences. We try to keep tabs on any IPO which dabbles in any of the 60 disruptive technology themes we research here at Nanalyze. Usually, we’ll have come across a company prior to their IPO announcement. Last May, we saw that ArcherDX took some funding, and we added them to our long list of topics to write about. Yesterday, they filed for an IPO, which means they now move to the front of the queue. ArcherDX hopes to apply personalized medicine to cancer treatment and make it available for all.

What does ArcherDX Do?

Click for company website

Founded in 2013, Boulder, Colorado startup ArcherDX has taken in a total of $150 million in funding so far to develop “a leading genomics company democratizing precision oncology.” In other words, they want to make personalized cancer testing available to everyone. As we’ve talked about before, the mythical “cure for cancer” doesn’t actually exist because each person’s cancer is unique. (The real cure for cancer is early detection, something we elaborated upon in our article on how Early Detection of Breast Cancer Cures Breast Cancer.) Personalized oncology promises a future where every cancer patient has their cancer genetical

Become a premium member and get access to hundreds of premium articles, reports and additional content.

Nanalyze Premium is your comprehensive guide to investing in disruptive technologies. Read by the top investment banks, management consultancies, VCs, and research houses. Trusted by over 100,000 institutional and retail investors. Covering disruptive technologies for over 18 years.